MDS Diagnosis via Peripheral Blood Flow Cytometry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing myelodysplastic syndromes (MDS) are complex and often elusive, requiring a multidisciplinary approach involving hematologic, morphologic, and cytogenetic analyses, with a lack of a single effective diagnostic assay for peripheral blood samples, and existing subjective testing methods are not sensitive or specific enough.
Innovation Solution
A method and kit for diagnosing MDS using multiparameter flow cytometric analysis of peripheral blood, analyzing predictive parameters such as cell granularity and expression of specific cell surface markers like CD66, CD11a, CD10, and CD116, assigning a numerical score based on comparisons to control samples to indicate the presence and severity of MDS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If complex immunophenotypic evaluation with extensive antibody panel is used, then diagnostic accuracy is improved, but device complexity and ease of operation deteriorate
Solution Approach 1:
The patent extracts and focuses on a specific subset of predictive parameters (CD66, CD11a, CD10, CD116) from the broader immunophenotypic evaluation, separating the essential diagnostic markers from the extensive antibody panel. This extraction simplifies the analysis while maintaining diagnostic accuracy for MDS detection.
Solution Approach 2:
The diagnostic approach is segmented into distinct analytical components: evaluating specific cell surface markers separately, assigning numerical scores based on predictive parameters, and comparing against control samples. This segmentation makes the complex diagnostic process more manageable and systematic.
2Reliability
If multidisciplinary approach involving hematologic, morphologic and cytogenetic analyses is used, then diagnostic reliability is improved, but ease of operation and time required deteriorate
Solution Approach 1:
The patent merges multiple diagnostic disciplines (hematologic, morphologic, cytogenetic) into a unified flow cytometric analysis system that evaluates predictive parameters simultaneously. This integration maintains diagnostic reliability while simplifying the operational process by consolidating multiple analyses into a single assay.
Solution Approach 2:
The flow cytometric analysis system serves multiple functions: it evaluates cell surface markers, assigns diagnostic scores, determines disease severity, and assesses therapy response. This multi-functionality replaces the need for separate specialized analyses, improving ease of operation while maintaining reliability.
3Ease of operation
If subjective testing methods are used, then ease of operation is improved, but measurement precision and specificity deteriorate
Solution Approach 1:
The patent implements an objective scoring system that provides quantitative feedback based on predictive parameter values. The numerical score assigned by comparing test samples to control samples eliminates subjectivity while maintaining ease of operation through automated or semi-automated evaluation criteria.
Solution Approach 2:
The diagnostic approach transitions from subjective evaluation to objective parameter measurement by quantifying cell surface marker expression levels. This parameter change enables precise, reproducible measurements that improve specificity while keeping the testing process simple through standardized scoring criteria.
4Measurement precision
If analysis of multiple cell types in bone marrow is performed, then diagnostic accuracy is improved, but loss of time and productivity deteriorate
Solution Approach 1:
The patent extracts the diagnostic evaluation from bone marrow analysis and applies it to peripheral blood samples. This extraction maintains diagnostic accuracy by focusing on predictive parameters that can be detected in peripheral blood, thereby eliminating the time-consuming bone marrow procedure while preserving diagnostic effectiveness.
Solution Approach 2:
Instead of analyzing bone marrow cells directly (the conventional approach), the patent inverts the approach by analyzing peripheral blood cells for predictive markers. This inversion achieves the same diagnostic accuracy with significantly improved productivity, as peripheral blood analysis is faster and less invasive.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a sensitive and specific diagnosis of MDS with 73% sensitivity and 90% specificity, distinguishing patients with MDS from controls with a high level of accuracy, and can assess the clinical course and response to therapy, integrating the heterogeneity of phenotypic changes in a simple and clinically applicable manner.
Implementation Method 1
Flow cytometric analysis in the evaluation of MDS has focused on complex immunophenotypic evaluation of the bone marrow
Data Source
AI summary
The present invention relates to methods and kits for diagnosing, ascertaining the clinical course a of myelodysplastic syndrome(MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides method and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS.